A previous epidemiological study on myasthenia gravis (MG) in Sardinia
indicated a prevalence rate of 4.5 per 100,000 population and an inci
dence of 0.25 per 100,000 population in the period 1958-1986. This stu
dy, however, investigated the entire Sardinian population (about 1,500
,000) and the reported rates are likely to be underestimated. Because
the use of a very large population has been found to cause major bias
in case finding, the present study was designed to overcome this bias
by determining the prevalence and incidence of MG in a well-defined ar
ea of Northwestern Sardinia, with a population of about 270,000 (1991
census). Potential MG cases were ascertained using all possible medica
l sources. The diagnosis of MG was based on the clinical, neurophysiol
ogical and conventional pharmacological findings (Tensilon test, respo
nse to anticholinesterases). On prevalence day (December 31, 1994) 29
MG patients were living in the study area (17 women and 12 men). Since
the total population on prevalence day was 268,926 (137,284 women and
131,642 men), the calculated prevalence was 11.1 per 100,000 populati
on (12.4 women and 9.9 men). The present study shows that the risk of
MG in Sardinia is higher than previously suggested. The risk, however,
is not significantly different from that found in other comparable It
alian and European areas. It contrasts with what has been found for ot
her autoimmune diseases such as multiple sclerosis and insulin-depende
nt diabetes mellitus in Sardinians, both showing frequencies up to 3-5
times higher than in the rest of Italy.